Hello. It's so exciting! We have so many posters. I think it's a total of 129 posters this year at the JADPRO Live conference. I walked through the poster halls, and I want to recap a few that caught my attention.
So, the first one is the US subgroup analysis from MagnetisMM-3 trial to evaluate the efficacy and safety of using less frequent dosing of elranatamab in relapsed and refractory myeloma. Among the 47 heavily pretreated patients who already received a median 5 prior lines of therapy, the overall response rate was 66%, and 42% achieved CR. Medium PFS is over 27 months. About half of the patients transition from weekly treatment down to every 3 to 4 weeks treatment, and most patients tolerate elranatamab very well, and CRS is only limited to grade 1 and 2.
One thing that stood out to me is the efficacy data of elranatamab in such a heavily pretreated subgroup. Despite 94% were triple-class refractory, and 47% were penta-drug refractory, those patients were able to remain in durable response even when the dosing schedule of elranatamab decreased to every 2 weeks, or even monthly treatment.
Using a less frequent dosing schedule may potentially result in fewer toxicities, reduce treatment burden, and improve patients' quality of life. The data of this study helps APPs to consider using elranatamab as a long-term management strategy in relapsed/refractory settings.
The second abstract is social needs screening in oncology, the results from a national insight-gathering with patients. This study surveyed 495 cancer patients to ask about their experience and expectations toward social needs screening in oncology care. And over half of the patients reported they discussed their social needs with their health-care providers, and 70 percent of the patient preferred verbal. conversations during their clinical visit.
Most patients believed financial and social needs should be assessed multiple times during their treatment courses. What surprised me was that nearly half of the patients reported they never been even asked about their financial or social support needs during their cancer treatment. So, this study reinforced the need to integrate social needs screening into routine cancer care as part of the holistic management.
APPs may take the lead to bridge medical and social aspects of cancer care to improve our patients' outcome. We can collaborate with social workers and other health-care professionals to create an open and safe environment to talk about those sensitive topics with our patients and help them connect it with available resources.
Another abstract I found interesting is the reviewing of their first year of multidisciplinary approach to outpatient bispecific T-cell engagement therapy program at a community oncology practice in Michigan. Since the launching of their program in April of 2024, 31 patients had already received bispecific step-up dosing in the outpatient setting. This abstract emphasizes the value of team-based collaborations between APPs, pharmacists and other health-care members.
I'm very impressed with the outcome of safely administrating bispecific antibody therapy as outpatient in the community oncology setting. The team developed innovative initiatives such as using a patient bracelet with a QR code to alert emergency team staff about the CRS and ICANS management protocols. This abstract highlights the critical role of APPs in the multidisciplinary team approach. And moving bispecific antibody therapy into outpatient community settings can expand access to treatment for our cancer patients.
